Table 1

Characteristics of patients with congenital cytomegalovirus (cCMV) infection

Screening for CMVRe-examination of CMVFirst MRI examinationSecond MRI examinationAABR
Pt noAge (days)Copies/mLAge (weeks)Copies/mLAge (weeks)FindingsAge (months)FindingsRightLeftOutcome*
1†11.9×10851.9×1086WMA, periventricular cysts27 WMA, ventriculomegalyR (−90 dB)‡PSNHL, PDD, speech delay
2†48.0×10627.2×10712WMA18 WMAR (−100 dB)R (−70 dB)SNHL, PDD, speech delay, calcification§
3†03.2×108242.5×10678WMA, ventriculomegaly, hippocampal dysplasiaDeclinedR (−80 dB)R (no response)SNHL, PDD, speech delay
4†44.8×10637.1×1074WMA18WMAR (−100 dB)PSNHL, PDD, speech delay
5†11.5×107322.1×1076WMA9WMA, cerebral parenchymal atrophyNDNDLate-onset hearing loss
614.1×106101.8×10612Polymicrogyria, ventriculomegaly, WMA18Polymicrogyria, WMA, ventriculomegaly, periventricular cystsPPLeft hemiparesis, PDD
721.0×10751.8×1088WMA18WMAPPMicrocephaly, speech delay
845.2×10592.0×1067WMA, vestibulo-semicircular canal dysplasiaNot yet done¶PP
918.0×106412.5×10740WMA, infarct18WMAPP
1042.1×10668.6×1077WMA, coagulation, necrosis around posterior horn of both lateral ventricles18WMAPP
1112.5×10655.3×1075WMA18WMA, ventriculomegalyPP
1213.1×107103.1×10712WMA18WMAPP
1322.0×10565.0×10411WMA18WMAPP
1443.3×10864.9×1076WMA18WMAPP
1545.4×10884.3×1086WMA18WMAPP
1641.3×10582.2×10611WMA18WMAPP
1741.0×10753.8×1067WMA18WMAPP
1831.3×10742.3×10612WMA19WMAPP
1945.7×10634.5×1063WMA9 WMAPP
2042.3×105No urine collection8WMA12WMAPP
2114.8×10759.4×1058WMA11WMAPP
2244.8×10751.1×1076WMA17WMANDND
2341.4×105101.4×10712WMA18WMAPP
2447.3×10457.6×1045WMA17WMAPP
2549.2×10461.1×1064WMA17WMAPP
2647.9×10581.5×1079WMA18WMAPP
2723.5×10463.5×10510WMA18NormalPP
2843.6×10583.4×10611WMA17NormalPP
2914.0×10791.8×10613WMA17NormalPP
3049.6×10451.1×1078WMA19NormalPP
3111.1×10692.1×10511WMA18NormalNDND
3211.6×10846.9×1075WMADeclinedPP
3341.9×10596.6×10514WMADeclinedPP
3445.1×106152.9×1057WMANot yet donePP
3543.7×10583.4×1058WMADeclinedPP
3641.1×10464.8×1058WMANot yet donePP
3713.9×10461.3×1055WMANot yet doneNDND
3811.5×107No urine collection7WMANot yet donePP
3946.9×107159.8×10614Normal20WMAPP
4011.1×109162.0×10718Normal18WMAPP
4113.5×107106.2×10613Normal17WMAPP
4246.7×10586.2×10510Normal24WMAPP
4343.6×10594.7×10611Normal22WMAPPCavum vergae
4421.4×10784.4×1059Normal18WMANDND
4546.1×10486.1×1047Normal16NormalPP
4643.8×104112.2×10616Normal18NormalPP
4741.2×106121.6×10712Normal17NormalPP
4814.5×10343.1×1054NormalDeclinedPP
4916.4×106144.1×10515NormalDeclinedPP
5047.4×105132.2×10628NormalDeclinedPP
5146.1×10431.2×1055NormalDeclinedPP
5241.1×106136.0×10612NormalNot yet donePP
5349.3×10573.9×1068NormalNot yet donePP
5411.1×104Not examined**Not examinedNot examinedPP
5513.1×106Not examinedNot examinedNot examinedPP
5632.4×106Not examinedNot examinedNot examinedPP
5747.7×106Not examinedNot examinedNot examinedPP
5842.4×103Not examinedNot examinedNot examinedPP
5911.0×104Not examinedNot examinedNot examinedNDND
6021.1×108Not examinedNot examinedNot examinedNDND
  • Microcephaly was noted in one newborn with modified HC z score of −2.95.

  • *No data means the patient had shown no apparent clinical manifestations until documentation of this paper.

  • †The oral antiviral drug valganciclovir was administered to patients 1–5 with SNHL for 5–6 months. Patient 5 presented with late-onset hearing loss and was then treated with valganciclovir.

  • ‡Figures in parentheses indicate hearing loss measured in decibel (dB).

  • §Calcification was confirmed with CT scan.

  • ¶Not yet done means that the second MRI examination is scheduled but had not yet been done until documentation of this paper.

  • **Not examined means no visit or examinations.

  • AABR, automatic auditory brainstem response; HC, nead circumference; nt, not tested; P, pass; PDD, psychomotor developmental delays; Pt no, patient number; R, refer; SNHL, sensorineural hearing loss; WMA, white matter abnormality.